Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 9/20 | 0.45 |
| ▸ | F2RL1 | P55085 | 1/20 | 0.31 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.30 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.30 |
| ▸ | FEN1 | P39748 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27395488 | 0.81 | DGAT1 (0.33) | DGAT1F2RL1NPC1 | |
| SCHEMBL30982174 | 0.81 | DGAT1 (0.33) | DGAT1F2RL1NPC1 | |
| SCHEMBL31092001 | 0.78 | DGAT1 (0.41) | DGAT1GRIN2B | |
| SCHEMBL24127736 | 0.78 | DGAT1 (0.34) | DGAT1NPC1 | |
| SCHEMBL31092009 | 0.75 | DGAT1 (0.39) | DGAT1 | |
| SCHEMBL31092003 | 0.75 | DGAT1 (0.39) | DGAT1 | |
| SCHEMBL25368440 | 0.74 | DGAT1 (0.41) | DGAT1F2RL1NPC1ALOX5APFEN1 | |
| SCHEMBL29626770 | 0.74 | GRIN1 (0.34) | DGAT1F2RL1GRIN1GRIN2BNPC1 | |
| SCHEMBL2598354 | 0.74 | GRIN1 (0.34) | DGAT1F2RL1GRIN1GRIN2BNPC1 | |
| SCHEMBL19617110 | 0.73 | DGAT1 (0.41) | DGAT1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114450271-B | Ureas, amino and substituted heteroaryl compounds for Cbl-b inhibition | 纽力克斯治疗公司 | 2024-09-20 | — | — | CN | disclosed |
| US-20220387395-A1 | UREA, AMIDE, AND SUBSTITUTED HETEROARYL COMPOUNDS FOR CBL-B INHIBITION | NURIX THERAPEUTICS, INC. | 2022-12-08 | — | — | US | disclosed |
| CN-114450271-A | Ureas, amino and substituted heteroaryl compounds for Cbl-b inhibition | 纽力克斯治疗公司 | 2022-05-06 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220387395-A1 | UREA, AMIDE, AND SUBSTITUTED HETEROARYL COMPOUNDS FOR CBL-B INHIBITION | CBLB, CBL, CBLC | DGAT1 3944/4885F2RL1 3960/4885GRIN1 4415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.